| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/HED.25932 |
| P698 | PubMed publication ID | 31573749 |
| P50 | author | Jason Chia-Hsun Hsieh | Q60965780 |
| Chun-Ta Liao | Q113027396 | ||
| P2093 | author name string | Kai-Ping Chang | |
| Chi-Ting Liau | |||
| Hung-Ming Wang | |||
| Pei-Hung Chang | |||
| Min-Hsien Wu | |||
| P2860 | cites work | Correlation between human papillomavirus and p16 overexpression in oropharyngeal tumours: a systematic review | Q26824273 |
| Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. | Q26827810 | ||
| Salivary biomarkers: toward future clinical and diagnostic utilities | Q26851200 | ||
| Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. | Q27851397 | ||
| Human papillomavirus and survival of patients with oropharyngeal cancer. | Q27851567 | ||
| Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. | Q27852333 | ||
| Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With [...] | Q27853302 | ||
| The mutational landscape of head and neck squamous cell carcinoma | Q29614654 | ||
| Fractional change in apparent diffusion coefficient as an imaging biomarker for predicting treatment response in head and neck cancer treated with chemoradiotherapy | Q30666523 | ||
| Platinum-based chemotherapy plus cetuximab in head and neck cancer | Q33381094 | ||
| Clinical trials for predictive medicine: new challenges and paradigms | Q33696732 | ||
| Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma. | Q33803297 | ||
| Hsp70--a biomarker for tumor detection and monitoring of outcome of radiation therapy in patients with squamous cell carcinoma of the head and neck | Q33824446 | ||
| Designing biomarker studies for head and neck cancer | Q33971467 | ||
| Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: prognostic and predictive significance | Q34020601 | ||
| XIAP is a predictor of cisplatin-based chemotherapy response and prognosis for patients with advanced head and neck cancer | Q34189300 | ||
| EGFR and cancer prognosis | Q34399312 | ||
| Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study | Q34471062 | ||
| High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck | Q34611571 | ||
| The cancer biomarker problem | Q34767213 | ||
| Dysregulated cholinergic network as a novel biomarker of poor prognostic in patients with head and neck squamous cell carcinoma. | Q35619485 | ||
| Kallikrein-related peptidase 6 regulates epithelial-to-mesenchymal transition and serves as prognostic biomarker for head and neck squamous cell carcinoma patients | Q35623800 | ||
| Prognostic Role of Circulating Tumor Cells during Induction Chemotherapy Followed by Curative Surgery Combined with Postoperative Radiotherapy in Patients with Locally Advanced Oral and Oropharyngeal Squamous Cell Cancer | Q35694837 | ||
| Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota | Q35833921 | ||
| Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma | Q36117785 | ||
| Metabolic tumor volume as a prognostic imaging-based biomarker for head-and-neck cancer: pilot results from Radiation Therapy Oncology Group protocol 0522. | Q36355220 | ||
| Role of EGFR as prognostic factor in head and neck cancer patients treated with surgery and postoperative radiotherapy: proposal of a new approach behind the EGFR overexpression. | Q36357543 | ||
| Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck | Q36500969 | ||
| Epidermal growth factor receptor biology in head and neck cancer | Q36500973 | ||
| Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients | Q36673460 | ||
| Serum midkine as a biomarker for malignancy, prognosis, and chemosensitivity in head and neck squamous cell carcinoma | Q36706828 | ||
| HPV infection in squamous cell carcinomas arising from different mucosal sites of the head and neck region. Is p16 immunohistochemistry a reliable surrogate marker? | Q36746765 | ||
| ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation | Q36755127 | ||
| Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma | Q36799986 | ||
| Significance of circulating tumor cells in patients with squamous cell carcinoma of the head and neck: initial results | Q37087791 | ||
| Platinum resistance: the role of DNA repair pathways | Q37100598 | ||
| Identification of a six microRNA signature as a novel potential prognostic biomarker in patients with head and neck squamous cell carcinoma | Q37225343 | ||
| ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial | Q37235591 | ||
| Oncogenic activities of human papillomaviruses | Q37316158 | ||
| EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer | Q37348956 | ||
| Effect of surgical intervention on circulating tumor cells in patients with squamous cell carcinoma of the head and neck using a negative enrichment technology | Q37427188 | ||
| MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol | Q37706078 | ||
| The molecular biology of head and neck cancer | Q37821229 | ||
| Emerging biomarkers in head and neck cancer in the era of genomics. | Q38268896 | ||
| HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis | Q38273669 | ||
| The prognostic value of cyclin D1 expression in head and neck squamous cell carcinoma. | Q38291222 | ||
| Automated RNA In Situ Hybridization for 18 High Risk Human Papilloma Viruses in Squamous Cell Carcinoma of the Head and Neck: Comparison With p16 Immunohistochemistry. | Q38372565 | ||
| Clinical implications of hypoxia biomarker expression in head and neck squamous cell carcinoma: a systematic review | Q38445971 | ||
| The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis. | Q38548142 | ||
| A liquid biopsy for head and neck cancers. | Q38657288 | ||
| Multiparametric magnetic resonance imaging in mucosal primary head and neck cancer: a prospective imaging biomarker study | Q38685910 | ||
| The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). | Q38686682 | ||
| PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma. | Q38699598 | ||
| Diagnostic and Prognostic Value of Circulating Tumor Cells in Head and Neck Squamous Cell Carcinoma: a systematic review and meta-analysis. | Q38718528 | ||
| FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma | Q38789317 | ||
| Detection of circulating tumor cells for prediction of recurrence after adjuvant chemoradiation in locally advanced squamous cell carcinoma of the head and neck | Q39154821 | ||
| Prognostic relevance of circulating tumor cells in blood and disseminated tumor cells in bone marrow of patients with squamous cell carcinoma of the oral cavity | Q39317145 | ||
| p16 expression in cutaneous squamous cell carcinoma of the head and neck is not associated with integration of high risk HPV DNA or prognosis. | Q39405599 | ||
| Bring on the biomarkers | Q39608553 | ||
| Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma | Q39985188 | ||
| Prognostic significance of head-and-neck cancer biomarkers previously discovered and identified using iTRAQ-labeling and multidimensional liquid chromatography-tandem mass spectrometry | Q39992556 | ||
| Immunohistochemical and molecular imaging biomarker signature for the prediction of failure site after chemoradiation for head and neck squamous cell carcinoma. | Q40070631 | ||
| External validation of sTWEAK as a prognostic noninvasive biomarker for head and neck squamous cell carcinoma. | Q40202959 | ||
| Candidate apoptotic and DNA repair gene approach confirms involvement of ERCC1, ERCC5, TP53 and MDM2 in radiation-induced toxicity in head and neck cancer | Q40269756 | ||
| Salivary soluble CD44: a potential molecular marker for head and neck cancer | Q40446867 | ||
| CDK4 in lung, and head and neck cancers in old age: evaluation as a biomarker | Q40488508 | ||
| Impact of p16 expression, nodal status, and smoking on oncologic outcomes of patients with head and neck unknown primary squamous cell carcinoma | Q40839526 | ||
| Association of ERCC1 polymorphisms (rs3212986 and rs11615) with the risk of head and neck carcinomas based on case-control studies | Q40892303 | ||
| Prognostic significance of Bcl-2 expression in localized squamous cell carcinoma of the head and neck | Q40893232 | ||
| Clinicopathological and prognostic significance of circulating tumor cells in patients with head and neck cancer: a meta-analysis | Q41348062 | ||
| Combination of p16(INK4a) /Ki67 immunocytology and HPV polymerase chain reaction for the noninvasive analysis of HPV involvement in head and neck cancer | Q41564660 | ||
| PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma | Q41592956 | ||
| Circulating tumor cells and CDX models as a tool for preclinical drug development | Q41605022 | ||
| Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder | Q41707195 | ||
| DNA Methylation at the Novel CpG Sites in the Promoter of MED15/PCQAP Gene as a Biomarker for Head and Neck Cancers. | Q42176436 | ||
| Concurrent radiotherapy plus epidermal growth factor receptor inhibitors in patients with human papillomavirus-related head and neck cancer | Q42257576 | ||
| ERCC1 protein expression is associated with differential survival in oropharyngeal head and neck squamous cell carcinoma. | Q42284398 | ||
| PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. | Q42369181 | ||
| Monitoring of circulating tumor cells and their expression of EGFR/phospho-EGFR during combined radiotherapy regimens in locally advanced squamous cell carcinoma of the head and neck | Q42506333 | ||
| Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck | Q43164702 | ||
| Prognostic value of cyclin D1 expression in tumor-free surgical margins in head and neck squamous cell carcinomas | Q43412784 | ||
| Prognostic role of epidermal growth factor receptor in head and neck cancer: a meta-analysis | Q43631346 | ||
| A novel panel of biomarkers predicts radioresistance in patients with squamous cell carcinoma of the head and neck | Q44156818 | ||
| Prognostic value of circulating tumor cells with podoplanin expression in patients with locally advanced or metastatic head and neck squamous cell carcinoma | Q44554262 | ||
| Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma | Q44569809 | ||
| Circulating tumour cells in locally advanced head and neck cancer: preliminary report about their possible role in predicting response to non-surgical treatment and survival. | Q45844676 | ||
| Prognostic value of ERCC1 in head and neck carcinoma treated with definitive or adjuvant radiotherapy. | Q45953377 | ||
| Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer | Q46502918 | ||
| Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer. | Q46518643 | ||
| Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer | Q46738588 | ||
| Meta analysis: HPV and p16 pattern determines survival in patients with HNSCC and identifies potential new biologic subtype | Q47106465 | ||
| Clinical significance of PD-L1+ exosomes in plasma of Head and Neck Cancer patients | Q47256356 | ||
| SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy | Q47736227 | ||
| Analysıs of gene copy number changes ın head and neck cancer. | Q47779019 | ||
| SOX2 activation predicts prognosis in patients with head and neck squamous cell carcinoma. | Q48157807 | ||
| A Collective Route to Head and Neck Cancer Metastasis | Q48240241 | ||
| Predictive biomarkers and EGFR inhibitors in squamous cell carcinoma of head and neck (SCCHN). | Q49998005 | ||
| ATM, BCL2, and TGFβ Gene Polymorphisms as Radiotherapy Outcome Biomarkers in Head and Neck Squamous Cell Carcinoma Patients | Q50033297 | ||
| Considerations About the Use of Biomarkers in Cancer Clinical Trials | Q50036265 | ||
| Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival | Q50054591 | ||
| Comprehensive review of genetic factors contributing to head and neck squamous cell carcinoma development in low-risk, nontraditional patients. | Q50087551 | ||
| Cell-free mitochondrial DNA copy number variation in head and neck squamous cell carcinoma: A study of non-invasive biomarker from Northeast India | Q50087962 | ||
| Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine. | Q50090313 | ||
| ERCC1 Expression Can Predict Response to Platinum-Based Induction Chemotherapy in Head and Neck Cancer Cases. | Q50899783 | ||
| Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation. | Q51791167 | ||
| Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck. | Q52533610 | ||
| SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy. | Q52624081 | ||
| p16(INK4a) status and survival benefit of EGFR inhibitors in head and neck squamous cell cancer: A systematic review and meta-analysis. | Q52651717 | ||
| The molecular landscape of head and neck cancer. | Q52678178 | ||
| Gene Expression Profiling in HPV-Positive p16-Positive Oropharyngeal Squamous Cell Carcinomas: A Path to Deintensification? | Q52715567 | ||
| Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population. | Q52814868 | ||
| Head and neck squamous cell carcinoma: Ambiguous human papillomavirus status, elevated p16, and deleted retinoblastoma 1. | Q52836574 | ||
| The presence of circulating tumor cells (CTCs) correlates with lymph node metastasis in nonresectable squamous cell carcinoma of the head and neck region (SCCHN). | Q52895988 | ||
| The development of a liquid biopsy for head and neck cancers. | Q53018887 | ||
| A novel saliva-based microRNA biomarker panel to detect head and neck cancers. | Q53025206 | ||
| Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. | Q53097632 | ||
| Epidermal growth factor receptor mutations in patients with oral cavity cancer in a betel nut chewing-prevalent area. | Q53270990 | ||
| Prognostic significance of cyclin D1 and p16 in patients with intermediate-risk head and neck squamous cell carcinoma treated with docetaxel and concurrent radiotherapy. | Q53547201 | ||
| Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. | Q53637394 | ||
| Melanoma differentiation-associated gene-7/interleukin-24 as a potential prognostic biomarker and second primary malignancy indicator in head and neck squamous cell carcinoma patients. | Q54195846 | ||
| Frameshift events predict anti-PD-1/L1 response in head and neck cancer. | Q54269200 | ||
| Epidermal growth factor receptor (EGFR) mutations as biomarker for head and neck squamous cell carcinomas (HNSCC). | Q54361563 | ||
| Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. | Q54494258 | ||
| VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. | Q54787856 | ||
| Expressional analysis of disease-relevant signalling-pathways in primary tumours and metastasis of head and neck cancers. | Q54979438 | ||
| Cultured circulating tumor cells and their derived xenografts for personalized oncology. | Q55059491 | ||
| Circulating Tumor Cell Analysis in Preclinical Mouse Models of Metastasis. | Q55601670 | ||
| TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. | Q55644910 | ||
| Artificial Intelligence for Drug Discovery, Biomarker Development, and Generation of Novel Chemistry | Q57059750 | ||
| Detection of circulating tumor cells in advanced head and neck cancer using the cellsearch system | Q57088453 | ||
| Measurement of circulating tumor cells in squamous cell carcinoma of the head and neck and patient outcomes | Q57136526 | ||
| Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching 'liquid biopsy' and quantitative tumor modeling | Q57154425 | ||
| Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinoma | Q57178166 | ||
| "Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach." | Q57279645 | ||
| Distinct co-expression networks using multi-omic data reveal novel interventional targets in HPV-positive and negative head-and-neck squamous cell cancer | Q57466150 | ||
| Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma | Q58093854 | ||
| Exposure to nicotine-derived nitrosamine ketone and arecoline synergistically facilitates tumor aggressiveness via overexpression of epidermal growth factor receptor and its downstream signaling in head and neck squamous cell carcinoma | Q58701669 | ||
| Differential impact of circulating tumor cells on disease recurrence and survivals in patients with head and neck squamous cell carcinomas: An updated meta-analysis | Q58759952 | ||
| Frequent HPV-independent p16/INK4A overexpression in head and neck cancer | Q58804797 | ||
| Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer | Q59274335 | ||
| Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression | Q59359495 | ||
| The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer | Q60949958 | ||
| Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: Implications for risk-based therapeutic intensity trials | Q64112550 | ||
| PD-1 and PD-L1 Expression Predicts Radiosensitivity and Clinical Outcomes in Head and Neck Cancer and is Associated with HPV Infection | Q64237924 | ||
| PRAD-1 (CCND1)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma | Q71997291 | ||
| Increased serum TWEAK levels in Psoriatic arthritis: relationship with disease activity and matrix metalloproteinase-3 serum levels | Q83057471 | ||
| Comparative prognostic value of epidermal growth factor quantitative protein expression compared with FISH for head and neck squamous cell carcinoma | Q83484121 | ||
| Transforming growth factor beta 1 genotype and p16 as prognostic factors in head and neck squamous cell carcinoma | Q84296982 | ||
| Reliable and effective diagnostics are keys to accelerating personalized cancer medicine and transforming cancer care: a policy statement from the american association for cancer research | Q85281016 | ||
| Predictive Role of ERCC1 Expression in Head and Neck Squamous Cell Carcinoma Patients Treated with Surgery and Adjuvant Cisplatin-Based Chemoradiation | Q85359875 | ||
| Plasma tumor necrosis factor-α and C-reactive protein as biomarker for survival in head and neck squamous cell carcinoma | Q87203465 | ||
| Arginase and C-reactive protein as potential serum-based biomarker of head and neck squamous cell carcinoma patients of north east India | Q87642243 | ||
| Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma | Q88310052 | ||
| RRM1 gene expression evaluated in the liquid biopsy (blood cfRNA) as a non-invasive, predictive factor for radiotherapy-induced oral mucositis and potential prognostic biomarker in head and neck cancer patients | Q88978855 | ||
| Prognostic Role of p16 in Nonoropharyngeal Head and Neck Cancer | Q89022300 | ||
| A clinical prognostic model compared to the newly adopted UICC staging in an independent validation cohort of P16 negative/positive head and neck cancer patients | Q89046074 | ||
| Evaluation of XRCC1 Gene Polymorphism as a Biomarker in Head and Neck Cancer Patients Undergoing Chemoradiation Therapy | Q89074168 | ||
| Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma | Q89222209 | ||
| Serum soluble TWEAK levels in severe traumatic brain injury and its prognostic significance | Q90153728 | ||
| Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study | Q90224620 | ||
| Artificial intelligence in healthcare | Q90254268 | ||
| Posttreatment surveillance PET/CT for HPV-associated oropharyngeal cancer | Q90484835 | ||
| Radiographic nodal prognostic factors in stage I HPV-related oropharyngeal squamous cell carcinoma | Q90537864 | ||
| Expression of CD44, EGFR, p16, and their mutual combinations in patients with head and neck cancer: Impact on outcomes of intensity-modulated radiation therapy | Q90537994 | ||
| Head and Neck Squamous Cell Carcinoma Detection and Surveillance: Advances of Liquid Biomarkers | Q90664639 | ||
| Evolving role of human papillomavirus as a clinically significant biomarker in head and neck squamous cell carcinoma | Q90692193 | ||
| Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy | Q90703327 | ||
| Role of Salivary Biomarkers in Oral Cancer Detection | Q91139644 | ||
| Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma | Q91149929 | ||
| Human papillomavirus and p16 immunostaining, prevalence and prognosis of squamous carcinoma of unknown primary in the head and neck region | Q91276135 | ||
| An Optically Induced Dielectrophoresis (ODEP)-Based Microfluidic System for the Isolation of High-Purity CD45neg/EpCAMneg Cells from the Blood Samples of Cancer Patients-Demonstration and Initial Exploration of the Clinical Significance of These Cel | Q91328955 | ||
| Expression of immune-regulatory molecules in circulating tumor cells derived from patients with head and neck squamous cell carcinoma | Q91407564 | ||
| The microRNA-375 as a potentially promising biomarker to predict the prognosis of patients with head and neck or esophageal squamous cell carcinoma: a meta-analysis | Q91476839 | ||
| HPV as a marker for molecular characterization in head and neck oncology: Looking for a standardization of clinical use and of detection method(s) in clinical practice | Q91477691 | ||
| Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma | Q92037447 | ||
| The change in circulating tumor cells before and during concurrent chemoradiotherapy is associated with survival in patients with locally advanced head and neck cancer | Q92568294 | ||
| Soluble siglec-5 is a novel salivary biomarker for primary Sjogren's syndrome | Q92684104 | ||
| Intraoperative liquid-based cytology of rinsed tissue fragments from head and neck lesions | Q92999223 | ||
| Co-expression of XIAP and CIAP1 Play Synergistic Effect on Patient's Prognosis in Head and Neck Cancer | Q93020979 | ||
| ERCC1, XPF and XPA-locoregional differences and prognostic value of DNA repair protein expression in patients with head and neck squamous cell carcinoma | Q93381163 | ||
| The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma | Q93382422 | ||
| P921 | main subject | biomarker | Q864574 |
| immunotherapy | Q1427096 | ||
| head and neck squamous cell carcinoma | Q18348812 | ||
| P304 | page(s) | 19-45 | |
| P577 | publication date | 2019-10-01 | |
| P1433 | published in | Head & Neck | Q13703062 |
| P1476 | title | Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy | |
| P478 | volume | 41 Suppl 1 |
| Q93054476 | Biological Determinants of Chemo-Radiotherapy Response in HPV-Negative Head and Neck Cancer: A Multicentric External Validation |
| Q99352687 | Metabolic tumor volume and total lesion glycolysis as prognostic factors in head and neck cancer: Systematic review and meta-analysis |
| Q91643917 | Regulation of Oncogenic Targets by miR-99a-3p (Passenger Strand of miR-99a-Duplex) in Head and Neck Squamous Cell Carcinoma |
Search more.